Physician profile
Sameh Attia
NPI 1396085700
$12,807.33
in general payments reported to CMS, 2019-2025
22 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $343 · 2021: $329 · 2022: $3,479 · 2023: $41.07 · 2024: $7,637 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,500 · Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,500.00 |
| Food and Beverage | $320.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,794.31 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $385.35 | 2019-2023 | Uptravi |
| Glaxosmithkline, LLC. | $352.93 | 2019-2022 | |
| Insmed, INC. | $227.67 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $156.34 | 2019-2025 | Fasenra |
| United Therapeutics Corporation | $111.23 | 2019-2022 | |
| Genentech USA, INC. | $102.11 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.69 | 2019-2022 | |
| Olympus America INC. | $77.86 | 2019-2022 | |
| Grifols USA, LLC | $69.92 | 2019-2022 | |
| Abbvie INC. | $69.38 | 2021-2022 | |
| Genzyme Corporation | $59.50 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $50.48 | 2019-2020 | |
| Mylan Specialty L.P. | $42.94 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $36.27 | 2024 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $33.19 | 2019 | |
| Sunovion Pharmaceuticals INC. | $30.70 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.02 | 2020-2021 | |
| Baxter Healthcare | $26.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.26 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.22 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameh Attia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.